Real-world comparative effectiveness of first-line abemaciclib versus palbociclib in HR+/HER2- metastatic breast cancer: A propensity-matched retrospective analysis.

ABSTRACT:

Background

In the first-line treatment of hormone receptor-positive, HER2-negative (HR+/HER2-) metastatic breast cancer (mBC), the comparative effectiveness of different cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) remains unclear due to the absence of head-to-head randomized trials. We aimed to compare the real-world outcomes of abemaciclib versus palbociclib.

Methods

We performed a retrospective, propensity-matched cohort study using the TriNetX Analytics Network database (2014-2025). The primary outcome was overall survival (OS). To ensure robust findings, the analysis was supported by multiple sensitivity tests, including restricted mean survival time (RMST) to provide a model-free effect measure, and E-value analysis to quantify the potential impact of unmeasured co

SUBMITTER: Lee CH 

PROVIDER: S-EPMC12550314 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature